Anavex Life Sciences Corp. (AVXL) Financials

AVXL Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 128.8 million 7.1 million
Dec. 31, 2025 133.0 million 6.4 million
Sept. 30, 2025 103.8 million 8.9 million
June 30, 2025 102.4 million 11.5 million

AVXL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 ? ?
Dec. 31, 2025 -7.2 million 1.1 million
Sept. 30, 2025 -8.6 million 3.7 million
June 30, 2025 -12.5 million 4.3 million

AVXL Net Income

No data available :(

AVXL Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 127.4 million - -
Dec. 31, 2025 131.7 million - -
Sept. 30, 2025 102.6 million - -
June 30, 2025 101.2 million - -

AVXL Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 92.7 million
Dec. 31, 2025 89.0 million
Sept. 30, 2025 85.9 million
June 30, 2025 85.4 million

AVXL Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 4.2 million 2.3 million -
Dec. 31, 2025 - 4.7 million 2.1 million -
Sept. 30, 2025 - 7.3 million 3.6 million -
June 30, 2025 - 10.0 million 4.5 million -

AVXL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - -

AVXL

Price: $3.22

52 week price:
2.26
11.70

Earnings Per Share: -0.39 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.1 million

Ebitda: -4.1 million

Market Capitalization: 316.1 million

Links: